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108 Poster Session-IIor chronic GVHD, CMV/other infections, graft rejection or overall
survival.We conclude that assessment ofMICAgene polymorphisms
in MRD alloBMT pts may have important implications for predict-
ing post-transplant outcomes. Thosewith aMICAdimorphism indi-
cating weak binding affinity for theNKG2D activating receptor may
have less alloreactive recipient immune effector cells that allow for
more rapid PE. This group may also be less likely to generate graft-
vs.-leukemia responses. Further investigation of this observation
with larger study populations is warranted.297
LONG–TERM SURVIVAL OF ALLOGENEIC TRANSPLANTATION(ALLO SCT)
IN SELECTED PATIENTS WITH MULTIPLE MYELOMA (MM): DISEASE
FREE SURVIVAL AT TWO YEARS MAY INDICATE LONG TERM SURVIVAL
Raychaudhuri, J., Perkins, J., Alsina, M., Ochoa-Bayona, J.L.,
Fernandez, H., Sullivan, D., Dalton, W., Kharfan-Dabaja, M.,
Field, T., Ayala, E., Perez, L., Harris, J.C., Janssen, W., Tate, C.,
Anasetti, C. H. Lee Moffitt Cancer Center and Research Institute, Tampa,
FL
Introduction: Allo SCT offers long term control and in some
cases cure in patients with MM. In this study we reviewed our expe-
rience at H. Lee Moffitt Cancer Center, of Allo SCT for MM and
examined indicators of long term survival.
Patient andMethods: A retrospective analysis was performed on
patients withMMwho underwent allo SCT between 1996 to 2008 at
our institution. Kaplan-Meier estimates were used to determine
overall and progression free survival.
Results:Thirty-one patients (18males and 13 females) underwent
AlloSCT for MM between 1996 and 2008. The median age was 45
years (range 29–63). The majority (64%) were Durie-Salmon stage
III at diagnosis. Most patients (74%) received at least 2 lines of prior
treatment and 16 received prior autologous transplant including 4
who received 2 autotransplants(2 out 4 were tandem).Disease status
prior to Allo SCT included 4 CR, 3 VGPR, 11 PR and 5\PR in the
data available in 23 patients. Ten patients had genetic high risk fea-
tures. 18 patients received matched related donors grafts (one synge-
neic) and 9 received matched unrelated donor grafts and 2 received
unrelated donors grafts mismatched at one allele. Eight patients
got TBI containing regimens and 2 patients Bu-Cy prior to 2002.
Subsequently either busulfan-fludarabine (5 patients) or melpha-
lan-fludarabine (12 patients) were used as conditioning regimens.
GVHD prophylaxis was tacrolimus plus methotrexate or mycophe-
nolate. Incidence of acute GVHD requiring treatment was 54.8%
and chronic GVHD was 42.8%. Non-relapse mortality at 100 days
was 22.5%. Post allograft the response levels were 12 CR, 3
VGPR, 2 PR, 7 \PR. Out of the 12 patients who achieved CR
post allograft 2 were VGPR, 2 were PR and 1 was progressive disease
prior to allogeneic transplant. Three patients were in continuingCR.
Overall survival at 1 year, 2 year, 5 year was 77%, 68%, and 54% re-
spectively. Event free survival at 1 year, 2 year, 5 year was 57%, 46%
and 46% respectively.
Conclusions:AlloSCT inMMallow for long term remissions and
survival in over 50% of patients treated with this approach. Relapses
are rare in those patients who remain in remission after 2 years. A
majority (4 out of 5 patients) of the long term survivors (.100
months) did get TBI containing regimens in this analysis. However
the melphalan-fludarabine patients look promising, but require lon-
ger follow up. A multivariate analysis of the prognostic factors is
ongoing.298
FOLLOW-UP OUTCOMES OF RELATED AND UNRELATED DONOR
HEMATOPOIETIC CELL TRANSPLANTATION FOR BETA-THALASSEMIA
PATIENTS
Vanichsetakul, P. Bangkok Hospital Medical Center, Bangkok, Thailand
Beta-thalassemia diseases are very prevalent in Thailand. Alloge-
neic hematopoietic stem cell transplantation (HCT) is the only ac-
ceptable therapeutic method to cure them. In this case-series study
there were 61 patients, one of which underwent HCTs twice
(BMT, then PBSCT) from same sibling donor. So, total 62 HCTs
were performed in single medical institute in Bangkok from July1999 to June 2008, including 42 BMTs, 9 PBSCTs, and 11 CBTs.
The detailed diagnoses were 54 cases of beta-thalassemia/hemoglo-
bin E, 6 of homozygous beta-thalassemia, and 1 of EFBart’s disease.
Patients’ age at transplant varied from18months to 14 years 8months
withmedian of 6 years. According to Pesaro classification, there were
25 class I, 27 class II, and 9 class III patients. Considering by donor
types, there were 34 patients in HLA-matched sibling, 2 in mis-
matched related cord blood, 22 in matched unrelated, 2 in one-anti-
gen mismatched unrelated cord blood, and 1 in mismatched
unrelated donor HCT groups. The mainstay of conditioning regi-
men contained busulfan (oral or intravenous), cyclophosphamide,
and anti-thymocyte globulin. Fludarabine was utilized in addtion
for most of unrelated donor HCT. Cyclosporine and methotrexate
were used as GVHDprophylaxis in matched related group, while ta-
crolimus was used instead of cyclosporine in unrelated group. 50 pa-
tients achieved donor engraftment and were considered as cured. 5
patients were alive but still with disease, and 6 patients died. Among
11 engrafted patients who previously developed acuteGVHD, only 1
matched-sibling PBSCT patient remained having chronic extensive
GVHD.Median follow-up time for surviving 55 patients was 3 years
3 months (range 4 months to 9 years 3months). To date the overall
(OS) and disease-free survival (DFS) for all patients were 90.2%
and 82%, respectively. Categorized by risk class, the OS and DFS
for class I patients were 92% and 88%, class II were 100% and
92.6%, and class III were 55.6% and 33.3%, respectively. Classified
by degree of HLA match, the OS and DFS for complete-matched
patients (n 5 56) were 92.9% and 87.5%, and mismatched patients
(n5 5) were 60% and 20%, respectively. In group of HLA-matched
HCT, the OS andDFS for patients receiving related donor stem cell
(n 5 34) were 97.1% and 94.1%, and ones getting unrelated donor
stem cell (n 5 22) were 90.9% and 81.8%, respectively. The fol-
low-up outcomes of these thalassemia patients have been convincing
as favorable and comparable to other studies.299
INTENSIVE PREPARATIVE REGIMEN EMPLOYING BUSULFAN, CYCLO-
PHOSPHAMIDE, AND TOTAL BODY IRRADIATION FOLLOWED BY ALLO-
GENEIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNANCIES
Yano, S.1, Usui, N.1, Dobashi, N.1, Yahagi, Y.1, Takei, Y.1,
Sugiyama, K.1, Ogasawara, Y.1, Takahara, S.1, Yamaguchi, Y.1,
Saito, T.1, Okawa, Y.1, Minami, J.1, Yokoyama, H.1, Kobayashi, T.1,
Otsubo, H.2, Hoshi, Y.2, Asai, O.1, Aiba, K.1 1Jikei University School of
Medicine, Tokyo, Japan; 2Jikei University School of Medicine, Tokyo,
Japan
Purpose: Intensive conditioning regimens given prior to alloge-
neic stem cell transplantation (allo-SCT) is able to bring durable re-
missions but increase treatment-related mortality (TRM). We
retrospectively evaluated the efficacy and safety of a conditioning
regimen consisting of busulfan (BU), cyclophosphamide (CY), and
total body irradiation (TBI) for patients with myeloid malignancies.
Patients and methods: FromNovember 1990 to February 2008,
85 patients (AML 38, CML 29,MDS 18) received BU (8mg/kg), CY
(120 mg/kg), and TBI (10 Gy) followed by related (n5 46) or unre-
lated (n5 39) allo-SCT. Patients with AML in 1st or 2nd remission,
CML in chronic phase, and MDS (less than 5%marrow blasts) were
defined as having a standard-risk group (n 5 55), and patients with
advanced diseases were defined as having a high-risk group (n5 30).
Results: Median follow-up was 8.4 (0.3–18.9) years, and median
age of patients was 35 (17–55) years old. The 8-year actuarial re-
lapse-free survival rates for all patients, standard-risk patients and
high-risk patients were 54%, 62% and 36%, respectively. Probabil-
ity of relapse rates for all patients, standard-risk patients and
high-risk patients were 22%, 14% and 42%, respectively. Hepatic
veno-occlusive disease was occurred in 3 patients (4%), and one of
them died of the disease. The cumulative incidence of TRM of all
patients was 26% (standard-risk 25%, high-risk 27%). Because
cytomegalovirus (CMV) disease was amajor cause of mortality follow-
ing allo-SCT before 1997, the incidence of TRM decreased to 13%
(standard-risk 10%, high-risk 16%) in the era of cytomegalovirus pre-
emptive therapy and no patient has died of CMV disease since 1998.
Conclusion:These results show that the combination of BU, CY,
andTBI seems to be one of effective intensive conditioning regimens
for allo-SCT in myeloid leukemia with a low TRM in the era of cy-
tomegalovirus preemptive therapy.
